Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The kidney research predicament.J Am Soc Nephrol. 2014; 25: 898-903
- Navigating toward research success in times of uncertainty: funding opportunities for early career investigators in nephrology.Am J Kidney Dis. 2015; 65: 381-383
- The kidney research national dialogue: gearing up to move forward.Clin J Am Soc Nephrol. 2014; 9: 1806-1811
- Rebuilding the pipeline of investigators in nephrology research in the United States.Clin J Am Soc Nephrol. 2018; 13: 1285-1287
- Enhancing nephrology career interest through the ASN kidney TREKS program.J Am Soc Nephrol. 2016; 27: 1604-1607
- Saving the endangered physician-scientist - a plan for accelerating medical Breakthroughs.N Engl J Med. 2019; 381: 399-402
- Training the physician-scientist: views from program directors and aspiring young investigators.JCI Insight. 2018; 3: e125651
- The Daunting career of the physician-investigator.Acad Med. 2017; 92: 1368-1370
- The clinical investigator as an endangered species.N Engl J Med. 1979; 301: 1254-1259
- Addressing the physician-scientist pipeline: strategies to integrate research into clinical training programs.J Clin Invest. 2020; 130: 1058-1061
- Canagliflozin and renal Outcomes in type 2 diabetes and Nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.Lancet. 2019; 393: 1937-1947
Financial Disclosures: A.A. serves as a consultant for DynaMed and serves on the medical advisory boards for Goldilocks Therapeutics, Angion, Reata, and Akebia. He also serves on the American Society of Nephrology council. S.R. declares that he has no relevant financial interests.
Support: See Acknowledgments on page 310.